rExenatide-4

also known as rE-4

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Comparator or background therapy1 trial
Phase 2	NCT01342042 Comparator	Mar → Dec 2011	type 2 diabetes mellitus	CSPC ZhongQi Pharmaceutical Technology Co., Ltd.	Unknown	No outcome recorded

Every value below carries the sentence it was read from. 2 sources stand behind the page.

Field	Value	Cited text
Known as	rExenatide-4	ClinicalTrials.gov intervention name — accepted as the source's own label NCT01342042 ↗
Known as	rE-4	“Recombinant glucagon-like peptide-1 receptor agonist (rE-4) is a glucagon-like peptide-1 receptor agonist, which has the same amino acid sequence to exenatide, except for the...” PMID 28932995 ↗ Dec 2017
Action	Activate	“rE-4) is a glucagon-like peptide-1 receptor agonist” PMID 28932995 ↗ Dec 2017
Modality	Protein / enzyme biologic	“This protein of 39 amino acids has been isolated from the venom of the lizard Heloderma suspectum (Gila monster)” NCT01342042 ↗
Route	Subcutaneous	“rE-4 and exenatide were administered by subcutaneous injection in the abdomen” PMID 28932995 ↗ Dec 2017